AR032891A1 - Compuesto derivado de hidroxiimino-fluoreno y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de proteinquinasa - Google Patents

Compuesto derivado de hidroxiimino-fluoreno y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de proteinquinasa

Info

Publication number
AR032891A1
AR032891A1 ARP010103906A ARP010103906A AR032891A1 AR 032891 A1 AR032891 A1 AR 032891A1 AR P010103906 A ARP010103906 A AR P010103906A AR P010103906 A ARP010103906 A AR P010103906A AR 032891 A1 AR032891 A1 AR 032891A1
Authority
AR
Argentina
Prior art keywords
compound
manufacture
substituted
treatment
fluorene
Prior art date
Application number
ARP010103906A
Other languages
English (en)
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of AR032891A1 publication Critical patent/AR032891A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems

Abstract

Compuesto derivado de hidroxiimino-fluoreno de la formula (1) donde R5 y R6 son cada uno independientemente hidrogeno, halo, o un C1-8 alquilo, C1-8 alcoxi, arilo, heteroarilo, acilo, tioalquilo, sulfonilo, o sulfoxil sustituido o no sustituido; y X es C-Y o N, en donde Y es hidrogeno, halo, NH2, NO2, o un alquilo, cicloalquilo, heterocicloalquilo, alcoxi, alquenilo, arilo, heteroarilo, ariloxi, alquilamino, dialquilamino, tioalquilo, acilo, sulfonilo, sulfoxido o tioarilo, sustituido o no sustituido; o un profármaco farmacéuticamente aceptado de dicho compuesto, un metabolito farmacéuticamente activo de dicho compuesto, o una sal farmacéuticamente aceptada de dicho compuesto o metabolito. Estos compuestos y las composiciones farmacéuticas que los contienen, son capaces de mediar la transduccion de la senal de la tirosina quinasa para modular y/o inhibir la proliferacion de las células indeseables. También se describe el uso de dichos compuestos en la fabricacion de medicamentos para el tratamiento del cáncer y las otras enfermedades asociadas con la angiogénesis y/o proliferacion celular indeseable, tales como la retinopatía diabética, el glaucoma neovascular, la artritis reumatoides y la psoriasis.
ARP010103906A 2000-08-18 2001-08-15 Compuesto derivado de hidroxiimino-fluoreno y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de proteinquinasa AR032891A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22480500P 2000-08-18 2000-08-18

Publications (1)

Publication Number Publication Date
AR032891A1 true AR032891A1 (es) 2003-12-03

Family

ID=22842288

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103906A AR032891A1 (es) 2000-08-18 2001-08-15 Compuesto derivado de hidroxiimino-fluoreno y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de proteinquinasa

Country Status (16)

Country Link
US (1) US6462060B2 (es)
EP (1) EP1309563B1 (es)
JP (1) JP2004506720A (es)
AR (1) AR032891A1 (es)
AT (1) ATE295354T1 (es)
AU (1) AU2001279090A1 (es)
BR (1) BR0113258A (es)
CA (1) CA2411924A1 (es)
DE (1) DE60110802T2 (es)
ES (1) ES2238463T3 (es)
GT (1) GT200100170A (es)
MX (1) MXPA03001452A (es)
PA (1) PA8525701A1 (es)
PE (1) PE20020289A1 (es)
SV (1) SV2003000603A (es)
WO (1) WO2002016326A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770652B2 (en) * 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
JP4502641B2 (ja) * 2002-01-24 2010-07-14 ティルタン ファーマ リミテッド 抗癌組み合わせおよびその使用方法
CA2542638A1 (en) * 2003-10-16 2005-04-28 Imclone Systems Incorporated Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
WO2006056889A2 (en) * 2004-10-06 2006-06-01 Tiltan Pharma Ltd Method and composition for enhancing anti-angiogenic therapy
ES2356068T3 (es) 2005-03-29 2011-04-04 Icos Corporation Derivados de heteroaril urea utiles para inhibir chk1.
WO2007026720A1 (ja) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. 縮環ピラゾール誘導体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
ATE262902T1 (de) 1994-11-10 2004-04-15 Millennium Pharm Inc Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
EP0888310B1 (en) 1996-03-15 2005-09-07 AstraZeneca AB Cinnoline derivatives and use as medicine
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
CN1160309C (zh) * 1996-05-30 2004-08-04 赫彻斯特马里恩鲁斯公司 烷氧基氨基取代的芴酮以及它们作为蛋白激酶c抑制剂的用途
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
EP0964864B1 (en) 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
CA2294244A1 (en) 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibiting purine derivatives
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
ES2206997T3 (es) 1997-10-06 2004-05-16 ABBOTT GMBH & CO. KG Derivados de indeno(1,2-c)-,de nafto(1,2-c),y de benzo(6,7)cicloepta(1,2-c)pirazol.
ES2267873T3 (es) 1997-10-27 2007-03-16 Agouron Pharmaceuticals, Inc. Derivados de 4-aminotiazol, su preparacion y uso como inhibidores de kinasas dependientes de ciclina.
ATE355841T1 (de) 1997-12-13 2007-03-15 Bristol Myers Squibb Co Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
DK1056745T3 (da) 1998-02-26 2004-10-25 Aventis Pharma Inc 6,9-Disubstituerede 2-[trans-(4-aminocyklohexyl)amino]puriner
BR9909597A (pt) 1998-04-21 2001-10-02 Du Pont Pharm Co Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
ATE336484T1 (de) 1998-08-29 2006-09-15 Astrazeneca Ab Pyrimidine verbindungen
US6316603B1 (en) * 1998-09-08 2001-11-13 Agouron Pharmaceuticals, Inc. Modifications of the VEGF receptor-2 protein and methods of use
PL348210A1 (en) * 1998-11-06 2002-05-06 Basf Ag Tricyclic pyrazole derivatives

Also Published As

Publication number Publication date
JP2004506720A (ja) 2004-03-04
MXPA03001452A (es) 2004-05-04
US20020049238A1 (en) 2002-04-25
DE60110802T2 (de) 2005-10-06
CA2411924A1 (en) 2002-02-28
GT200100170A (es) 2002-05-16
BR0113258A (pt) 2003-07-15
SV2003000603A (es) 2003-01-13
PA8525701A1 (es) 2002-04-25
WO2002016326A1 (en) 2002-02-28
DE60110802D1 (de) 2005-06-16
AU2001279090A1 (en) 2002-03-04
ES2238463T3 (es) 2005-09-01
ATE295354T1 (de) 2005-05-15
PE20020289A1 (es) 2002-05-27
US6462060B2 (en) 2002-10-08
EP1309563A1 (en) 2003-05-14
EP1309563B1 (en) 2005-05-11

Similar Documents

Publication Publication Date Title
AR032438A1 (es) Compuesto derivado de indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento para tratar enfermedades proteinquinasa dependientes
AR042510A1 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
UY26190A1 (es) Compuestos de tiazol y composiciones farmacéuticas para inhibir a las proteinquinasas y métodos para su utilización
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
BRPI0012352B8 (pt) compostos de indazol ou sal farmaceuticamente aceitável e composição farmacêutica
SK17252002A3 (sk) Deriváty acylfenylmočoviny, spôsoby ich výroby a použitie ako liečivo
CN108024974B (zh) 含有dna烷化剂的氮丙啶
PA8510201A1 (es) Compuestos de amida y composiciones farmacèuticas para inhibir proteinquinasas, y su modo de empleo
MY148937A (en) Medicaments with hm74a receptor activity
AR053770A1 (es) Pirimidinas como antagonistas del receptor de prostaglandina d2. composiciones farmaceuticas.
BR9910915A (pt) Composto, processos para preparar um composto e para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica
GT200400136A (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibirlaproliferacion celular.
KR930702292A (ko) 종양 치료 활성을 증대시키기 위한 퀴나졸린 유도체
EP1259487B8 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
BR9808010B1 (pt) Compostos de 2-alquil-19-nor-vitamina d e composição farmacêutica compreendendo os mesmos
UY25993A1 (es) Procedimiento para preparar derivados del acido hidroxi-pipecolato hidroxamico
AR032763A1 (es) Compuestos pirazol-tiazol, composicion farmaceutica que lo contiene, y el uso de dicho compuesto en la fabricacion de medicamentos para inhibir quinasas ciclino-dependientes
AR032891A1 (es) Compuesto derivado de hidroxiimino-fluoreno y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de proteinquinasa
DK1194415T3 (da) Nye piperazinylalkylthiopyrimidinderivater, farmaceutiske sammensætninger indeholdende disse samt en fremgangsmåde til deres fremstilling
SE1550735A1 (en) Ether analogues of galiellalactone
FR2679907B1 (fr) Nouveaux n-[(isoquinolein-5 yl)sulfonyl] azacycloalcanes, leur procede de preparation et les compositions pharmaceutiques les contenant.
CN101230015B (zh) 含酰胺取代基的取代桂皮酸衍生物及其肿瘤细胞毒性
CA3036852A1 (en) Dithio etp derivatives
ES2184730T3 (es) Nuevo derivado del acido aminofenilacetico, produccion del mismo, y modulador de respuesta inmune que contiene este derivado como ingrediente activo.
ATE335491T1 (de) Arzneimittel gegen glomerulosclerose

Legal Events

Date Code Title Description
FB Suspension of granting procedure